Evidence map›Paper›PMID 41193702›Full record

ReviewHypertension research : official journal of the Japanese Society of Hypertension2026

Current updates on latest basic research of scientific relevance in hypertensive dementia.

Masaki Mogi, Yoichi Takami, Masafumi Ihara, Toru Yamashita, Shuko Takeda, Shigeru Shibata, Kouichi Node, Kazuomi Kario, Prevention of Cognitive Impairment by Hypertension Management (PCIHM) Working Group of the Japanese Society of Hypertension

Erratum issuedAbstract readReviewReview
PubMed Publisher
In one paragraph

Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Angiotensin receptor blockers and dementia risk in older adults: A target trial emulation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Recent topics in hypertensive dementia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  3. Blood pressure variability will start cognitive impairment.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  4. Article
  5. Cumulative Blood Pressure as a Marker of Early Cognitive Decline.Journal of clinical hypertension (Greenwich, Conn.) · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Masaki MogiDeparment of Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan. mogi.masaki.me@ehime-u.ac.jp.
Yoichi TakamiDepartment of Geriatric and General Medicine, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Masafumi IharaDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Toru YamashitaDepartment of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Okayama, Japan.
Shuko TakedaDepartment of Clinical Gene Therapy, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
Shigeru ShibataDivision of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Kouichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga, Saga, Japan.
Kazuomi KarioDivision of Cardiovascular Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
Prevention of Cognitive Impairment by Hypertension Management (PCIHM) Working Group of the Japanese Society of Hypertension

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schematic presentation of possible mechanisms of hypertensive dementia, including amyloid beta metabolism (A), NVU dysfunction (B), vulnerability of the hippocampus (C), and activation of RAS (D), and possible new therapeutic approaches for discovering antihypertensive drugs with anti-dementia actions (E). See text for details. Aβ, amyloid β; APP, amyloid β precursor protein; BACE1, β-site amyloid precursor protein cleaving enzyme 1; BBB, blood-brain barrier; CBF, cerebral blood flow; eNOS, endothelial nitric oxide synthase; FDA, Food and Drug Administration; IL, interleukin; NOX, NADPH oxidase; NVU, neurovascular unit; RAS, renin-angiotensin system; ROS, reactive oxygen species.

Indexed as

DementiaHypertensionAmyloid beta-PeptidesAnimalsAntihypertensive AgentsBlood-Brain BarrierCerebrovascular CirculationHippocampusHumansNootropic AgentsRenin-Angiotensin SystemAmyloid beta-PeptidesAntihypertensive AgentsNootropic AgentsAmyloid beta metabolismAntihypertensive drugHypertensive dementiaImplemental hypertensionNeurovascular unit

Identifiers

PMID41193702

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.